NeurAxis Completes $5 Million Registered Direct Offering
NeurAxis, Inc. (NYSE American: NRXS) is proud to announce a significant milestone in its financial journey, having secured $5.0 million through a registered direct stock offering. This strategic move allows NeurAxis to continue its mission of pioneering neuromodulation therapies aimed at alleviating chronic and debilitating medical conditions that affect both children and adults.
Overview of the Offering
The company plans to sell 1,538,461 shares of its common stock at a price of $3.25 per share. The offering is expected to close shortly under standard conditions and regulations within the market sector. Craig-Hallum Capital Group will serve as the exclusive placement agent for this offering.
Utilization of Funds
NeurAxis intends to allocate the net proceeds from this offering for essential working capital and to support its general corporate activities. This financial boost is expected to enhance the company's capabilities in advancing its innovative therapies, such as the IB-Stim™, which focuses on addressing functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8 to 21.
A Commitment to Advancing Neuromodulation Therapies
NeurAxis remains steadfast in its dedication to improving the quality of life for patients suffering from chronic pain and debilitating conditions. The company leverages evidence-based medicine to encourage the adoption of its proprietary therapeutic solutions. The IB-Stim™ technology, which employs Percutaneous Electrical Nerve Field Stimulation (PENFS), has received FDA clearance, marking a significant achievement in its offerings.
Clinical Trials and Future Prospects
In addition to the existing treatments available through IB-Stim™, NeurAxis is actively pursuing further clinical trials. These trials are aimed at expanding the application of PENFS across a wider range of pediatric and adult conditions, addressing substantial unmet healthcare needs. This commitment to research and development is crucial as the industry evolves and new challenges arise.
Legal and Regulatory Considerations
NeurAxis has diligently prepared for this stock offering by filing a shelf registration statement with the U.S. Securities and Exchange Commission (SEC). This legal preparation is designed to ensure compliance with regulations and provides investors with significant insights into the company's planned use of the offering's proceeds.
Investor Communication
To enhance transparency and keep stakeholders informed, NeurAxis is committed to timely communication regarding the outcomes of this offering and its implications on the company's future endeavors. Investors can look forward to detailed information following the closing of the offering.
Frequently Asked Questions
What is the purpose of NeurAxis's recent stock offering?
The offering aims to raise $5 million, which will be allocated to working capital and corporate purposes, particularly in enhancing its neuromodulation therapies.
What are the key highlights of the IB-Stim™ therapy?
IB-Stim™ is FDA cleared for treating functional abdominal pain related to IBS in adolescents aged 8-21, showcasing NeurAxis's commitment to addressing significant health issues.
Who is managing the stock offering for NeurAxis?
Craig-Hallum Capital Group is the exclusive placement agent for this offering, facilitating the process and ensuring compliance with market standards.
How does this offering affect NeurAxis's development plans?
The funds raised from the offering will play a vital role in advancing NeurAxis’s R&D efforts and in bringing innovative therapies to market to serve patient needs better.
What is NeurAxis's goal with its neuromodulation therapies?
NeurAxis aims to improve health outcomes for patients with chronic conditions through innovative and evidence-based treatment options, fulfilling an important unmet need in healthcare.
